Reviving therapies With Untapped Potential

Contact

Mission

Many promising therapies never reach patients-not because they failed, but because funding disappeared, priorities shifted, acquisitions occurred or new leadership took a different direction.

Resurgent Therapeutics Advisory exists to identify those opportunities & help organizations build practical, efficient, evidence-based paths towards clinical development & ultimately commercial success.

Services

  • Magnifying glass with a black handle resting on a light blue surface, signifying strategic asset assessment services.

    Strategic Asset Assessment

    Independent evaluation of therapeutic assets, development plans & risks, competitive positioning & value creation opportunities

  • Medical items including a stethoscope and a blue pill bottle on white background, signifying clinical development planning services

    Clinical Development Planning

    Design efficient development pathways including Pre-IND & Phase I-III planning, indication prioritization, protocol strategy & operational guidance

  • Top-down view of a busy wooden desk with multiple laptops, smartphones, notebooks, coffee cups, and various office supplies, signifying due diligence services.

    Due Diligence

    Scientific & clinical diligence and deep data review for investors, licensors & acquisition teams evaluating therapeutic programs

  • Orange upholstered chairs arranged around a light wooden conference table in a modern board room setting, signifying fractional Chief Development Officer services.

    Fractional Chief Development Officer

    Executive leadership for emerging biotechnology companies that need experienced strategic support without hiring a full-time executive

Who We Work With

  • Close-up digital illustration of a DNA double helix structure with colorful molecular particles, representing genetic material or molecular biology.

    Emerging Biotech

  • Black and white photo of three people in conversation inside a high-rise building with large windows, overlooking a city skyline with tall buildings and partly cloudy sky. Represents big pharma clients.

    Pharma BD teams

  • A clear glass cup filled with coins, with a small green plant growing from the coins, near a window. Represents venture capital clients.

    Venture Capital

  • Close-up of a computer screen displaying a candlestick chart with green and red bars, used for stock trading or financial analysis.

    Private Equity

  • Close-up of a pipette dispensing pink liquid into a row of small, clear plastic test tubes in a laboratory setting. Representing academic spinoff clients.

    Academic Spinouts

  • People working on laptops and reviewing handwritten notes on a desk during a meeting or collaborative work session. Representing family office clients.

    Family Offices

About

A photograph of the Founder of the company.

Michael Mandola, Ph.D. - Founder & Principal Consultant

Mike Mandola, PhD, is a biopharmaceutical executive with more than 20 years of oncology experience spanning program leadership, clinical development, business development, global corporate partnerships & medical strategy. He most recently served as Senior Vice President, Head of Program Strategy & Leadership at Merck Healthcare, following progressive leadership roles at Bristol Myers Squibb.

Currently he serves as a Scientific Advisory Board member in biotech & Strategic Innovation Board member for The Max Foundation, a non-profit focused on providing life-saving cancer medications to low- and middle- income countries.

During his tenure in pharma, Mike worked across oncology programs spanning pre-IND to post-marketing. Mike has led numerous due diligence exercises, including taking the helm as Program Leader for successful partnerships.

Mike holds a PhD in Molecular Biology from the University of Medicine and Dentistry of NJ (now Rowan University) and a BS in Biology from Stockton University. He conducted his post-doctoral research at the Fox Chase Cancer Center and The Cancer Institute of NJ.